Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field
Trip"), a leader in the development and delivery of psychedelic
therapies, is pleased to announce the launch of “KAP Co-op”, a
program that enables eligible independent psychedelic therapists to
provide ketamine-assisted psychotherapy (and, in the future, other
legal, psychedelic-assisted therapies) at its Field Trip Health
centers. Field Trip is also pleased to announce the launch of
training programs designed to provide interested psychotherapists
or other qualified mental health professionals and clinicians with
access to best-in-class training on KAP.
KAP Co-op Program
Under the KAP Co-op Program, independent
therapists who are experienced at providing psychedelic-assisted
therapies, or who completed approved training programs through
providers including MAPS, Fluence, The Ketamine Training Center and
the California Institute for Integral Studies (CIIS), amongst
others, are eligible to become a co-operative therapist with Field
Trip (“Co-op Therapists”).
Once approved, Co-op Therapists will have access
to Field Trip’s world class centers for psychedelic therapies and
other resources from Field Trip to provide KAP to their own private
practice clients (“Co-op Clients”).
Co-op Clients will be able to access Field
Trip’s medical teams for the screening, prescribing and
administration/dispensation of ketamine, while continuing to
receive all preparation and integration therapy from their existing
therapist.
The cost of the medical screening and ketamine
administration/dispensation at a Field Trip Health center for Co-op
Clients will be available for an introductory price of $400 for a
limited period. The cost of the preparation and integration therapy
will be established directly between the Co-op Client and the Co-op
Therapist as part of their existing therapeutic relationship within
the therapist’s private practice.
“The launch of the KAP Co-op Program extends
Field Trip’s presence to a whole new population of therapists and
their clients who want to have the Field Trip experience and access
our world class Field Trip Health centers,” said Hannan Fleiman,
Field Trip’s President. “Now, instead of operating in parallel to
existing client-therapist relationships, Field Trip is working on a
truly complementary and co-operative basis to the incredible work
all psychedelic therapists are doing with their clients.”
Training Programs
Field Trip’s training programs will provide a
blend of didactic and experiential training for the delivery of
KAP, and will be provided over the course of a weekend (Friday -
Sunday). Topics covered in the training programs will include:
preparation for psychedelic therapy, techniques for guiding a
psychedelic experience, and integration of insights from a
psychedelic experience.
The first session of Field Trip’s therapist
training program will take place on the weekend of October 8, 2021
in Seattle, WA, and will cost $1,200 USD. Future sessions will be
announced at a later time and will be held at Field Trip’s various
Field Trip Health center locations.
“Many therapists are eager to get practical,
hands-on experience with psychedelic-assisted therapies so they can
confidently start offering these powerful modalities to their
clients,” said Dr. Ryan Yermus, Field Trip’s Chief Clinical
Officer. “Presently, however, the options available for training
are limited and are either cost prohibitive, infrequent, long or do
not include hands-on training. With the launch of Field Trip’s
training programs, we are making training for therapists accessible
and affordable. But what is even more exciting is with the launch
of our KAP Co-operative Program, therapists will be able to quickly
put that training to use.”
“Therapists are on the frontline of the global
mental health crisis. And everyday more evidence confirms that the
best tools we have to address this crisis are psychedelic-assisted
therapies,” said Ronan Levy, Field Trip’s Executive Chairman. “The
best thing we can be doing right now is to equip an army of
therapists with what they need to deliver these powerful therapies.
And that’s exactly what Field Trip is doing. Through our training
programs and our KAP Co-op Program, any qualified therapist that
wants to provide psychedelic-assisted therapies will have access to
the training, facilities and medical resources they need to do
so.”
“I genuinely believe that in 20 years we might
look back and see that the launch of these programs, along with the
incredible progress we are making in advancing the science and
understanding of psychedelic molecules such as FT-104, marked a
turning point in the mental health crisis we are battling,” he
added.
Therapists and clinicians interested in
participating in KAP Co-op or Field Trip’s training programs should
send an indication of interest to coop@fieldtriphealth.com or
training@fieldtriphealth.com, respectively.
About Field Trip Health Ltd.
Field Trip is a global leader in the development
and delivery of psychedelic therapies. With our Field Trip
Discovery division leading the development of the next generation
of psychedelic molecules and conducting advanced research on
plant-based psychedelics and our Field Trip Health division
building centers for psychedelic therapies opening across North
America and Europe along with the digital and technological tools
that will enable massive scale, we help people in need with a
simple, evidence-based way to heal and heighten engagement with the
world.
Learn more at https://www.meetfieldtrip.com,
https://www.fieldtriphealth.com and
https://www.fieldtriphealth.nl.
Follow us on Twitter and Instagram:
@fieldtriphealth
To receive company updates about Field Trip and
to be added to the email distribution list please sign up here.
Cautionary Note Regarding
Forward-Looking Information
This release includes forward-looking
information (within the meaning of Canadian securities laws and
within the meaning of the United States Private Securities
Litigation Reform Act of 1995) regarding Field Trip and its
business. Often but not always, forward-looking information can be
identified by the use of words such as "expect", "intends",
"anticipated", "believes" or variations (including negative
variations) of such words and phrases, or state that certain
actions, events or results "may", "could", "would" or "will" be
taken, occur or be achieved. Such statements are based on the
current expectations and views of future events of the management
of Field Trip, and are based on assumptions and subject to risks
and uncertainties. Although the management of Field Trip believes
that the assumptions underlying these statements are reasonable,
they may prove to be incorrect. The forward-looking events and
circumstances discussed in this release may not occur and could
differ materially as a result of known and unknown risk factors and
uncertainties affecting the companies, including interest in the
training program, interest in the KAP Co-Op Program, uptake of the
KAP Co-Op Program by therapists and patients, the timing and
results of its research and development programs, approval of phase
1 human trials, if any, the risk that future clinical studies may
not proceed as expected or may produce unfavorable results, the
opening of additional clinics, the COVID-19 epidemic, the medical
clinic industry, market conditions, economic factors, management's
ability to manage and to operate the business and the equity
markets generally. Although Field Trip has attempted to identify
important factors that could cause actual actions, events or
results to differ materially from those described in
forward-looking statements, there may be other factors that cause
actions, events or results to differ from those anticipated,
estimated or intended. Accordingly, readers should not place undue
reliance on any forward-looking statements or information. No
forward-looking statement can be guaranteed. Except as required by
applicable securities laws, forward-looking statements speak only
as of the date on which they are made and Field Trip does not
undertake any obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy securities.
Neither the Toronto Stock Exchange, nor its
Regulation Services Provider, have approved the contents of this
release or accept responsibility for the adequacy or accuracy of
this release.
Media contacts:Rachel MoskowitzAutumn
Communications202-276-7881press@fieldtriphealth.com
Nick Opich / McKenna MillerKCSA Strategic
Communications212-896-1206 /
347-487-6197press@fieldtriphealth.com
Investor contacts:Elizabeth BarkerKCSA
Strategic Communications212-896-1203ebarker@kcsa.comSOURCE Field
Trip Health Ltd.
Field Trip Health (NASDAQ:FTRP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Field Trip Health (NASDAQ:FTRP)
Historical Stock Chart
From Apr 2023 to Apr 2024